Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

已完结 10 由 Aven 发布于 2026/10/22 19:39:56

DOI:10.1016/S1470-2045(22)00518-6
作者：Mary O'Brien,?Luis Paz-Ares,?Sandrine Marreaud,?Urania Dafni,?Kersti Oselin,?Libor Havel,?Emilio Esteban,?Dolores Isla,?Alex Martinez-Marti,?Martin Faehling,?Masahiro Tsuboi,?Jong-Seok Lee,?Kazuhiko N
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer (NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC.Met

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyEfficient and Scalable Detection of Microplastics in Drinking Water Using Fluorescence High-Content Imaging